EP1546714A4 - Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer - Google Patents

Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer

Info

Publication number
EP1546714A4
EP1546714A4 EP02799873A EP02799873A EP1546714A4 EP 1546714 A4 EP1546714 A4 EP 1546714A4 EP 02799873 A EP02799873 A EP 02799873A EP 02799873 A EP02799873 A EP 02799873A EP 1546714 A4 EP1546714 A4 EP 1546714A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
therapy
compositions
methods
human cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02799873A
Other languages
German (de)
French (fr)
Other versions
EP1546714A1 (en
Inventor
Wadih Arap
Mikhail G Kolonin
Paul J Mintz
Renata Pasqualini
Amado J Zurita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/027836 external-priority patent/WO2003022991A2/en
Application filed by University of Texas System filed Critical University of Texas System
Publication of EP1546714A1 publication Critical patent/EP1546714A1/en
Publication of EP1546714A4 publication Critical patent/EP1546714A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP02799873A 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer Withdrawn EP1546714A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2002/027836 WO2003022991A2 (en) 2001-09-07 2002-08-30 Compositions and methods of use of targeting peptides against placenta and adipose tissues
WOPCT/US02/27836 2002-08-30
PCT/US2002/034987 WO2004020999A1 (en) 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer

Publications (2)

Publication Number Publication Date
EP1546714A1 EP1546714A1 (en) 2005-06-29
EP1546714A4 true EP1546714A4 (en) 2007-12-05

Family

ID=31975571

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02799873A Withdrawn EP1546714A4 (en) 2002-08-30 2002-10-30 Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer

Country Status (4)

Country Link
EP (1) EP1546714A4 (en)
AU (1) AU2002364501A1 (en)
CA (1) CA2496938A1 (en)
WO (1) WO2004020999A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322559A3 (en) 2002-07-04 2011-08-03 Patrys Limited Neoplasm specific antibodies and uses thereof
DE10311248A1 (en) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Human monoclonal antibody
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (en) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Human monoclonal antibody with fatliquoring effect
WO2005065418A2 (en) * 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
JP5479087B2 (en) * 2006-04-07 2014-04-23 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Methods and compositions for adeno-associated virus phage particles
JP5374360B2 (en) 2007-02-27 2013-12-25 中外製薬株式会社 Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient
WO2009155556A2 (en) * 2008-06-20 2009-12-23 The Board Of Regents Of The University Of Texas System Crkl targeting peptides
CN102120755B (en) * 2010-04-23 2013-04-03 江苏省人民医院 Brown adipose tissue targeted polypeptide and applications thereof
CN113278731A (en) * 2021-05-12 2021-08-20 广西医科大学 lncRNA marker for judging antiviral treatment effect of HIV-1 infected person and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020822A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
WO2002020769A1 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) * 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6093800A (en) * 1996-09-06 2000-07-25 The Regents Of The University Of California E25a protein, methods for production and use thereof
US6261789B1 (en) * 1997-03-10 2001-07-17 The Regents Of The University Of California Methods for detecting the presence of a PSCA protein using PSCA antibodies
US6372720B1 (en) * 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020822A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
WO2002020769A1 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display
WO2002020724A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Adenoviral targeting and manipulation of immune system response using targeting peptides
WO2002020723A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas System Compositions and methods for targeting peptides in humans in vivo
WO2002020722A2 (en) * 2000-09-08 2002-03-14 Board Of Regents, The University Of Texas Syste Methods and compositions for in vitro targeting

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004020999A1 *

Also Published As

Publication number Publication date
CA2496938A1 (en) 2004-03-11
AU2002364501A1 (en) 2004-03-19
EP1546714A1 (en) 2005-06-29
WO2004020999A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1571968A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1589933A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1478276A4 (en) Novel targeted compositions for diagnostic and therapeutic use
EP1515982A4 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1572091A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1578996A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1551990A4 (en) Diagnosis and treatment of chemoresistant tumors
EP1575571A4 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1516049A4 (en) Compositions and methods for the therapy and diagnosis of lung cancer
EP1539251A4 (en) Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1546714A4 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP1532162A4 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
EP1420814A4 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2003230849A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
GB0326578D0 (en) Cancer diagnosis and therapy
AU2003260301A8 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003279312A8 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003295902A8 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071105

17Q First examination report despatched

Effective date: 20080514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080925